We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+19.81%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.35B
AUM Growth
+$99.6M
Cap. Flow
-$51.8M
Cap. Flow %
-3.83%
Top 10 Hldgs %
51.22%
Holding
199
New
40
Increased
30
Reduced
31
Closed
45

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$43.2M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.8M
3
BAX icon
Baxter International
BAX
+$15.5M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$13.3M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$11.5M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$22.7M
2
RLYP
RELYPSA INC COM
RLYP
+$18.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$17.6M
4
CEMP
Cempra, Inc.
CEMP
+$16.2M
5
SHPG
Shire pic
SHPG
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 86%
2 Consumer Discretionary 0.08%
3 Financials 0.04%
4 Consumer Staples 0.02%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYNH
176
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
– –
-7,261
Closed -$290K
NUVA
177
DELISTED
NuVasive, Inc.
NUVA
– –
-252
Closed -$12K
CYAD
178
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
– –
-75,000
Closed -$3.14M
CNCE
179
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-10,379
Closed -$195K
HSTO
180
DELISTED
Histogen Inc. Common Stock
HSTO
– –
-2
Closed -$2K
AMAG
181
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-2,904
Closed -$115K
WCG
182
DELISTED
Wellcare Health Plans, Inc.
WCG
– –
-2,189
Closed -$189K
DVCR
183
DELISTED
Diversicare Healthcare Services Inc
DVCR
– –
-12,337
Closed -$127K
SGYP
184
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-226,000
Closed -$1.2M
AET
185
DELISTED
Aetna Inc
AET
– –
-2,586
Closed -$283K
JNP
186
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
– –
-1,736
Closed -$20K
CEMP
187
DELISTED
Cempra, Inc.
CEMP
– –
-582,500
Closed -$16.2M
STJ
188
DELISTED
St Jude Medical
STJ
– –
-51,520
Closed -$3.25M
RLYP
189
CALL
DELISTED
RELYPSA INC COM
RLYP
– –
-300,000
Closed -$5.55M
RLYP
190
DELISTED
RELYPSA INC COM
RLYP
– –
-987,942
Closed -$18.3M
RLYP
191
PUT
DELISTED
RELYPSA INC COM
RLYP
– –
-250,000
Closed -$4.63M
THOR
192
CALL
DELISTED
THORATEC CORPORATION
THOR
– –
-100,000
Closed -$6.33M
THOR
193
DELISTED
THORATEC CORPORATION
THOR
– –
-86,000
Closed -$5.44M
SHPG
194
DELISTED
Shire pic
SHPG
– –
-41,000
Closed -$8.41M
RPRX
195
DELISTED
Repros Therapeutics Inc.
RPRX
– –
-220,000
Closed -$1.64M
4 5 6 7
8

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Perceptive Advisors held 199 positions worth $1.35B, up 8% from $1.25B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors withdrew a net $51.8M in Q4 2015, closing 45 positions and reducing 31 holdings. Its most notable exit was RELYPSA INC COM, an estimated $18.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 78% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Perceptive Advisors opened a new position in Allergan plc worth $45.3M.

  • Perceptive Advisors's largest Q4 2015 buy was Allergan plc: 145,000 shares worth $45.3M.
  • Perceptive Advisors added most to Teva Pharmaceuticals in Q4 2015, an estimated $19.8M increase.
  • Perceptive Advisors's biggest Q4 2015 reduction was Neurocrine Biosciences, cutting an estimated $22.7M.
  • Perceptive Advisors fully exited RELYPSA INC COM in Q4 2015, selling an estimated $18.3M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $1.35B portfolio in Q4 2015.
  • Perceptive Advisors opened 40 new positions and closed 45 in Q4 2015.
  • Perceptive Advisors's portfolio value rose 8% quarter-over-quarter to $1.35B.

Based on Perceptive Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.